![]() ![]() “Based on the experience of the workgroup, we believe that bone-modifying agents were still widely being dosed on a monthly schedule, where there’s substantial evidence that you don’t need to dose them monthly, you can dose them quarterly,” said Felasfa Wodajo, MD, chair of Evidence-Based Medicine at MSTS and guideline co-chair. Reducing the Dosing Frequency of Bone-Modifying Agents Studies conducted on at least 10 patients were included in the review. Guideline recommendations were based on a systematic review of clinical trials and observational studies published between January 1946 and July 2019, and clinical experience. On June 20, 2020, ASCO approved the first joint Musculoskeletal Tumor Society (MSTS)/American Society of Radiation Oncologists (ASTRO)/ASCO guideline on the care of patients with metastatic carcinoma and myeloma of the femur.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |